SCM Lifescience Co., Ltd.
π°π·South Korea
A Long-term Safety Follow-up Study of SCM-AGH in Patients Who Completed SCM-APT2001 Study
Active, not recruiting
- Conditions
- Pancreatitis, Acute
- First Posted Date
- 2023-07-21
- Last Posted Date
- 2023-11-28
- Lead Sponsor
- SCM Lifescience Co., LTD.
- Target Recruit Count
- 42
- Registration Number
- NCT05955235
- Locations
- π°π·
Chonnam National University Medical School, Gwangju, Korea, Republic of
π°π·Soonchunhyang University Hosptial Bucheon, Bucheon, Gyenggi-do, Korea, Republic of
π°π·Kyungpook National University Chilgok Hospital, Daegu, Korea, Republic of
Safety and Efficacy of SCM-AGH in Patients With Moderate to Severe Acute Pancreatitis
Phase 1
Completed
- Conditions
- Pancreatitis, Acute
- Interventions
- Other: PlaceboBiological: SCM-AGH
- First Posted Date
- 2019-12-06
- Last Posted Date
- 2023-06-08
- Lead Sponsor
- SCM Lifescience Co., LTD.
- Target Recruit Count
- 36
- Registration Number
- NCT04189419
- Locations
- π°π·
Inha University Hospital, Incheon, Korea, Republic of
π°π·Wonju Severance Christian Hospital, Wonju, Korea, Republic of
π°π·Soonchunhyang University Hosptial Bucheon, Bucheon, Gyenggi-do, Korea, Republic of
Efficacy and Safety of SCM-CGH in Patients With Steroid-Refractory or Dependent Chronic Graft-Versus-Host Disease
Phase 2
Active, not recruiting
- Conditions
- Chronic Graft-versus-host-disease
- Interventions
- Other: PlaceboBiological: SCM-CGH
- First Posted Date
- 2019-12-06
- Last Posted Date
- 2023-06-08
- Lead Sponsor
- SCM Lifescience Co., LTD.
- Target Recruit Count
- 84
- Registration Number
- NCT04189432
- Locations
- π°π·
Kyungpook National University Hospital, Daegu, Korea, Republic of
π°π·Inha University Hospital, Incheon, Korea, Republic of
π°π·Asan Medical Center, Seoul, Korea, Republic of
Long-Term Safety Follow-Up Study of SCM-AGH in Subjects Who Participated and Administered SCM-AGH in to Severe Atopic Dermatitis Clinical Trials
- Conditions
- Dermatitis, Atopic
- First Posted Date
- 2019-12-04
- Last Posted Date
- 2021-03-17
- Lead Sponsor
- SCM Lifescience Co., LTD.
- Target Recruit Count
- 92
- Registration Number
- NCT04185584
- Locations
- π°π·
Inha University Hospital, Incheon, Korea, Republic of
Safety and Efficacy of SCM-AGH in Subjects With Moderate to Severe Atopic Dermatitis
Phase 1
Completed
- Conditions
- Dermatitis, Atopic
- Interventions
- Biological: SCM-AGHOther: Placebo
- First Posted Date
- 2019-11-27
- Last Posted Date
- 2023-06-08
- Lead Sponsor
- SCM Lifescience Co., LTD.
- Target Recruit Count
- 92
- Registration Number
- NCT04179760
- Locations
- π°π·
Inha University Hospital, Incheon, Korea, Republic of
Β© Copyright 2025. All Rights Reserved by MedPath